TOPIC:

From a presentation at the latest AASLD conference:


www.hcplive.com/conference-coverage/aasl...gimen-for-genotype-3

So, the new ALLY 3+ is different to ALLY 3 because of the sign (+) that stands for Riba addition to the double DAA tx ?

From the article:

"Hepatitis C’s genotype 3 can be hard to cure, but researchers presenting a study at the Liver Meeting (AASLD) in San Francisco, CA, said they have found a regimen that works. Vincent LeRoy, MD, of the Centre Hospitalier Universitaire de Grenoble, La Tronche France, and colleagues at other institutions reported on a trial known as ALLY-3+.

Fifty patients with HCV-GT-3 were treated and most had already had other treatments.
The patients got daclatasvir (Daklinza/Bristol-Myers-Squibb) sofosbuvir (Sovaldi/Gilead) and ribavirin (Rebetol/Merck).

One arm of the group got the combo for 12 weeks and showed SVR4 rate of 88%.
A second group took the drugs for 16 weeks and their SVR4 rate was 96%.
There were no virologic breakthroughs.

In an abstract presented at the meeting, the team concluded that the combination therapy “Achieved high SVR4 rates” in patients with HCV GT3 with compensated advanced fibrosis or cirrhosis “and was generally safe and well tolerated.”

The extra 4 weeks makes a difference then ?

That's what the trial appears to be saying.

Oh, so now I see that was what Dr James was referring to in my appointment last week. I'm G3a, F0-F1, he's prescribed the Sof/Dac but said instead of the usual 12 weeks I should do 16 weeks because the SVR4 had higher rate of success in recent research.

Thanks for that article.